Indeed, lenvatinib and the anti-PD-1 antibody, pembrolizumab combination therapy showed effective antitumor activity; subsequently, it was approved for endometrial cancer7 and renal cell carcinoma (RCC)8. Here, PDCD1 is linked to renal cell carcinoma.